Biogen’s Challenges and Cautious Outlook: Hold Rating Amid Revenue Growth Struggles and Neurology Market Hurdles
In a report released today, Evan Seigerman from BMO Capital downgraded Biogen (BIIB – Research Report) to a Hold, with a price target of ...
BMO cuts rating on Merck and Biogen, on lack of near term catalyst
BMO Capital Markets downgraded Merck &Company Inc (NYSE:MRK) to "market perform" from "outperform," citing concerns over its Gardasil franchise in China and uncertainty around filling the revenue gap ...
Biogen downgraded to Market Perform from Outperform at BMO Capital
BMO Capital downgraded Biogen (BIIB) to Market Perform from Outperform with a price target of $164, down from $230. Work is underway at Biogen, ...
Biogen in talks to move to MIT's Volpe development, sources say
Biogen is in advanced negotiations to consolidate its Kendall Square operations in MIT’s upcoming Volpe redevelopment, ...
The Pharma Letter2d
Leqembi creator to work with Bristol Myers in $1.3 billion deal
Bristol Myers Squibb acquires global rights to BioArctic’s Alzheimer’s antibody candidates BAN1503 and BAN2803 for up to $1.3 ...
조선일보2d
Seoul Asan Medical Center starts prescribing Alzheimer's drug Leqembi
Seoul Asan Medical Center said it started prescribing the early Alzheimer's disease drug "Leqembi" (generic name lecanemab) ...
FierceBiotech2d
BMS pays Leqembi originator $100M for next-gen preclinical Alzheimer's prospects
Bristol Myers Squibb has turned to the source of Leqembi to further its push into Alzheimer’s disease, paying BioArctic $100 ...
BioArctic announces global license agreement with Bristol Myers Squibb for BioArctic's PyroGlutamate-amyloid-beta antibody program
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that it has entered into a global exclusive license agreement with Bristol ...
Eli Lilly's Alzheimer's treatment approved in China
China's medical regulator has approved Eli Lilly's treatment for early Alzheimer's, providing patients with another option ...
pharmaphorum3d
Lilly's Alzheimer's drug Kisunla is cleared in China
China is the fourth major market where Kisunla has been approved after the US, Japan, and GB. It gets the green light there ...
Eli Lilly Alzheimer's therapy approved in China
Eli Lilly (LLY) stock in focus as China approves its Alzheimer's treatment Kisunla (donanemab). Read more here.
EconoTimes3d
Eli Lilly’s Kisunla Approved in China, Paving the Way for Innovative Alzheimer’s Treatment Options
China has approved Eli Lillys Kisunla, marking another milestone in global efforts to address Alzheimers disease. The ...